Agonists of different PPAR subtypes are known to be well established in the therapy of metabolic disorders such as obesity [15], insulin resistance, and atherosclerosis [16], which are inextricably linked to the development of MASLD and often develop simultaneously. This evidence concerns the gene PPARA and obesity disorder.